Tofacitinib, a JAK1/3 Inhibitor As Treatment for Linear IgA Bullous Dermatosis: A Case Report.

导出 LinkOut

翻译打印收藏纠错

作者： Birao,Fan ^[1] ; Mingyue,Wang ^[2]

作者单位： Department of Dermatology, Peking University First Hospital, Beijing, China. ^[1] National Clinical Research Center for Skin and Immune Diseases, Beijing, China. ^[2] Beijing Key Laboratory of Molecular Diagnosis on Dermatoses, Beijing, China. ^[3] Department of Dermatology, Peking University First Hospital, Xishiku Street, Xicheng District, Beijing 100034, China. ^[4]

主题词人类(Humans);哌啶类(Piperidines);嘧啶类(Pyrimidines);Janus激酶1(Janus Kinase 1)

DOI 10.1089/derm.2022.29007.bfa

PMID 36917531

发布时间 2023-07-18

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Dermatitis

160-161页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Tofacitinib, a JAK1/3 Inhibitor As Treatment for Linear IgA Bullous Dermatosis: A Case Report.

Dermatitis

相似文献

Dermatitis

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Tofacitinib, a JAK1/3 Inhibitor As Treatment for Linear IgA Bullous Dermatosis: A Case Report.

Dermatitis

相似文献

Dermatitis

相关期刊

检索历史清除